UOB Kay Hian analysts Lucas Teng and John Leong have maintained their “buy” call on Raffles Medical Group with an unchanged target price of $1.07.  The analysts called the group a “laggard on the recovery theme” and expect local patient load to reach “normalised levels that are on a p...

With a viable Covid-19 vaccine seemingly just around the corner, global investors are increasingly switching out of growth plays towards value stocks. Despite signs of optimism in market laggards, UOB KayHian analyst Adrian Loh urges investors to buy into blue chips with strong financials and divide...

Member for Parliament for East Coast GRC and Deputy Speaker of Parliament Jessica Tan Soon Neo has been appointed as a non-executive independent director and a member of the investment committee at Ascendas India Trust. In an SGX filing on Nov 20, the board of Ascendas Property Fund Trustee says tha...

RAFFLES Medical Group announced on Wednesday that it has appointed Kenneth Wu and Chong Ee Rong as co-deputy managing directors of operations and commercial respectively.

RAFFLES Medical Group announced on Wednesday that it has appointed Kenneth Wu and Chong Ee Rong as co-deputy managing directors of operations and commercial respectively.

Following a share price correction, Maybank Kim Eng Research analyst Lai Gene Lih has upgraded Raffles Medical Group to “buy” on improved risk-reward. Lai’s target price on the medical services provider, however, remains unchanged at 99 cents. “RMG’s key sustainability factor is ensuring p...

The irrational exuberance of surplus liquidity has finally come to an end, as most markets corrected sharply following a sell-off in technology stocks. But according to OCBC’s head of research Carmen Lee, Singapore stocks could prove a safe harbour to tide over stronger headwinds in the face of mo...

Singapore Exchange Regulation (SGX RegCo) has issued a query to Raffles Education after its shares spiked up to as high as 15.1 cents on September 8, at 2.33pm, representing a 32.5% jump from its last closed share price of 11.4 cents the day before. During the period, around 5.6 million shares chang...

PhillipCapital is maintaining its “neutral” call on Raffles Medical with a revised target price of 94 cents. This is down 5 cents or 5.05% from its previous 99 cent call, analyst Tay Wee Kuang says in a July 29 note. He believes the revised price will give the company a 4.9% upside from its 92 c...

ANALYSTS from Maybank Kim Eng and CGS-CIMB have downgraded their calls on Raffles Medical Group, citing insufficient upside.